达安基因：间接控股股东拟变为广药集团

Group 1 - The core point of the news is that Guangzhou Pharmaceutical Group intends to acquire a controlling stake in Da An Gene, which will result in the group controlling approximately 26.63% of the company's total shares [1] - The acquisition involves Guangzhou Pharmaceutical Group indirectly controlling about 233 million shares of Da An Gene through Guangzhou Guangyong Technology Development Co., Ltd. and acquiring an additional 70.17 million shares from Guangzhou Financial Holdings Group and Guangzhou Health Industry Investment [1] - After the completion of this equity change, the actual controlling shareholder will remain the Guangzhou Municipal Government, with Guangzhou Guangyong Technology still being the controlling shareholder [1] Group 2 - For the first half of 2025, Da An Gene's revenue composition shows that the bioproducts sector accounts for 95.68% of total revenue, while financial services contribute 4.32% [2] - As of the latest report, Da An Gene has a market capitalization of 9.7 billion yuan [3]